{"id":"atazanavir-ritonavir-monotherapy","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hyperbilirubinemia"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1200678","moleculeType":"Small molecule","molecularWeight":"802.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir is an HIV protease inhibitor that blocks the viral protease enzyme required for processing HIV polyproteins into functional viral proteins, thereby preventing viral maturation and replication. Ritonavir is a potent CYP3A4 inhibitor used at sub-therapeutic doses to increase atazanavir plasma concentrations, allowing for lower atazanavir dosing and improved pharmacokinetics. This combination is being evaluated as monotherapy to simplify HIV treatment regimens.","oneSentence":"Atazanavir/ritonavir inhibits HIV protease to prevent viral replication, with ritonavir boosting atazanavir levels through CYP3A4 inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:45.686Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (monotherapy maintenance in virologically suppressed patients)"}]},"trialDetails":[{"nctId":"NCT01511809","phase":"PHASE3","title":"Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2010-09","conditions":"HIV-1 Infection","enrollment":117},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ATV/r monotherapy"],"phase":"phase_3","status":"active","brandName":"Atazanavir/ritonavir monotherapy","genericName":"Atazanavir/ritonavir monotherapy","companyName":"IRCCS San Raffaele","companyId":"irccs-san-raffaele","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atazanavir/ritonavir inhibits HIV protease to prevent viral replication, with ritonavir boosting atazanavir levels through CYP3A4 inhibition. Used for HIV-1 infection (monotherapy maintenance in virologically suppressed patients).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}